By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Flow cytometry technology firm LeukoDx today announced it has secured commitments of up to $8 million in investments during the next three years.

The funding is expected to bring the company's development of its point-of-care platform to the point of registration, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.